Skip to main content
MAYNE PHARMA GROUP LIMITED logo

MAYNE PHARMA GROUP LIMITED — Investor Relations & Filings

Ticker · MYX ISIN · AU000000MYX0 LEI · 549300VIRDEN0N4MJG59 ASX Manufacturing
Open in API
Filings indexed 1,118 across all filing types
Latest filing 2025-05-11 Director's Dealing
Country AU Australia
Listing ASX MYX

About MAYNE PHARMA GROUP LIMITED

https://www.maynepharma.com

Mayne Pharma Group Limited is a specialty pharmaceutical company focused on the development and commercialization of branded and generic medicines. The company operates through specialized segments including Women's Health and Dermatology. Its Women's Health portfolio features innovative contraceptive solutions, while the Dermatology division provides a broad range of treatments for various skin conditions. Beyond its product portfolio, the company provides contract development and manufacturing services (CDMO), leveraging proprietary drug delivery technologies to produce complex oral and topical dosage forms. The organization focuses on high-growth specialty markets, aiming to deliver differentiated therapeutic options and improve patient outcomes through technical excellence and strategic commercialization.

Recent filings

Filing Released Lang Actions
Response to ASX Query 4 pages 433.6KB
Director's Dealing Classification · 100% confidence The document is a letter from ASX Compliance to Mayne Pharma Group Limited regarding a late lodgement of Appendix 3Y, which is a Change of Director's Interest Notice. The letter requests explanations and details about compliance with Listing Rules 3.19A and 3.19B concerning timely disclosure of directors' interests. The content focuses on regulatory compliance and disclosure obligations related to director share transactions, not on financial results, management changes, or other report types. The document is a regulatory inquiry and correspondence about insider trading disclosures, fitting the category of Director's Dealing (DIRS). The document length (8806 characters) and content confirm it is not a brief announcement or a report publication notice but a substantive regulatory communication about director share transactions.
2025-05-11 English
HSR closing condition satisfied for scheme of arrangement 1
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 7 May 2025 from Mayne Pharma Group Limited regarding an update on a proposed scheme of arrangement with Cosette Pharmaceuticals. It specifically states that the Hart-Scott-Rodino Antitrust Improvements Act waiting period has expired, satisfying a closing condition for the scheme. The announcement references prior announcements and outlines remaining conditions for the scheme's implementation. The content is focused on a corporate transaction update rather than a full report, financial statements, or detailed merger documentation. It is not a full merger filing (MA) or tender offer but an update on a financing/transaction condition. Therefore, the document fits best under Capital/Financing Update (CAP) as it provides an update on a financing-related transaction condition being met.
2025-05-06 English
Notification of cessation of securities - MYX 4 pages 14.8KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 3H - Notification of cessation of securities' and details the lapse of performance rights securities for Mayne Pharma Group Limited. It provides specific information about the securities that have ceased, the reason for cessation, and the updated issued capital following these changes. This type of announcement is a regulatory filing notifying the market and shareholders about changes in the company's securities, specifically the cessation of certain securities. It does not contain financial statements, management discussion, or detailed financial results. It is not an annual report, earnings release, or any form of financial report. It is also not a director dealing or share issue announcement but rather a cessation notification. Given the nature and format, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-05-06 English
Change of Director's Interest Notice 2 pages 281.1KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares disposed and held after the change. The content focuses on personal share transactions by a company director. There is no financial performance data, earnings information, or report publication. The document fits the definition of 'Director's Dealing' which reports personal share transactions by company directors and executives (insider trades). The document length is 3387 characters, which is consistent with a notice rather than a full report. Therefore, the correct classification is DIRS.
2025-05-06 English
Change in substantial holding 6 pages 269.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under Corporations Law Section 671B. It details changes in voting power and relevant interests of UBS Group AG and its related bodies corporate in Mayne Pharma Group Limited. The document includes tables of shareholdings, changes in relevant interests, and associated agreements. This type of filing is a notification of changes in significant share ownership levels, which corresponds to a Major Shareholding Notification. The document is not a financial report, earnings release, or management report, but a regulatory disclosure of shareholding changes.
2025-04-27 English
Business update, new licensing and updated scheme timetable 4 pages 189.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement from Mayne Pharma providing a business update including unaudited financial results for the third quarter and nine months of FY25, details of a new licensing agreement, and an updated timetable for a Scheme of Arrangement. It contains financial performance data (unaudited), forward-looking statements, and operational updates but does not present a full audited financial report or comprehensive financial statements. The document also includes details about a licensing agreement and scheme timetable, which are typical of a business update or capital/financing update. The length is about 9,882 characters, which is substantial but the content is primarily an update and not a full annual or interim report. It is not a full earnings release since it includes more detailed operational and strategic updates beyond key highlights. It is not a regulatory filing or report publication announcement since it contains substantive financial data and business updates. Therefore, the best fit is Capital/Financing Update (CAP) because it includes financial performance updates, licensing agreement details, and scheme timetable updates related to corporate transactions.
2025-04-21 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.